HALO
Income statement / Annual
Last year (2023), Halozyme Therapeutics, Inc.'s total revenue was $829.25 M,
an increase of 25.62% from the previous year.
In 2023, Halozyme Therapeutics, Inc.'s net income was $281.59 M.
See Halozyme Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$829.25 M
|
$660.12 M
|
$443.31 M
|
$267.59 M
|
$195.99 M
|
$151.86 M
|
$316.61 M
|
$146.69 M
|
$135.06 M
|
$75.33 M
|
| Cost of Revenue |
$192.36 M |
$139.30 M |
$81.41 M |
$43.37 M |
$45.55 M |
$10.14 M |
$31.15 M |
$33.21 M |
$29.25 M |
$22.73 M |
| Gross Profit |
$636.89 M |
$520.81 M |
$361.90 M |
$224.23 M |
$150.45 M |
$141.73 M |
$285.46 M |
$113.49 M |
$105.81 M |
$52.60 M |
| Gross Profit Ratio |
0.77 |
0.79 |
0.82 |
0.84 |
0.77 |
0.93 |
0.9 |
0.77 |
0.78 |
0.7 |
| Research and Development
Expenses |
$76.36 M
|
$66.61 M
|
$35.67 M
|
$34.24 M
|
$140.80 M
|
$150.25 M
|
$150.64 M
|
$150.84 M
|
$93.24 M
|
$79.70 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$60.80 M
|
$53.82 M
|
$45.85 M
|
$40.03 M
|
$35.94 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$149.18 M
|
$143.53 M
|
$50.32 M
|
$45.74 M
|
$77.25 M
|
$60.80 M
|
$53.82 M
|
$45.85 M
|
$40.03 M
|
$35.94 M
|
| Other Expenses |
$73.77 M |
$43.15 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$299.32 M |
$253.28 M |
$86.00 M |
$79.97 M |
$218.06 M |
$211.06 M |
$204.46 M |
$196.70 M |
$133.26 M |
$115.64 M |
| Cost And Expenses |
$491.68 M |
$392.59 M |
$167.41 M |
$123.34 M |
$263.60 M |
$221.19 M |
$235.61 M |
$229.90 M |
$162.51 M |
$138.37 M |
| Interest Income |
$0.00 |
$15.90 M |
$6.42 M |
$14.95 M |
$7.11 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$18.76 M |
$16.95 M |
$7.53 M |
$20.38 M |
$11.63 M |
$18.04 M |
$21.98 M |
$19.98 M |
$5.20 M |
$5.58 M |
| Depreciation &
Amortization |
$84.86 M
|
$49.64 M
|
$3.00 M
|
$3.28 M
|
$4.07 M
|
$2.39 M
|
$2.16 M
|
$2.41 M
|
$1.68 M
|
$1.76 M
|
| EBITDA |
$451.95 M
|
$315.51 M
|
$259.04 M
|
$152.96 M
|
-$56.56 M
|
-$69.33 M
|
$83.16 M
|
-$79.47 M
|
-$25.35 M
|
-$61.03 M
|
| EBITDA Ratio |
0.55 |
0.47 |
0.62 |
0.54 |
-0.34 |
-0.46 |
0.26 |
-0.57 |
-0.2 |
-0.84 |
| Operating Income Ratio
|
0.41
|
0.41
|
0.62
|
0.54
|
-0.34
|
-0.46
|
0.26
|
-0.57
|
-0.2
|
-0.84
|
| Total Other
Income/Expenses Net |
$10.76 M
|
-$18.61 M
|
-$27.38 M
|
-$14.95 M
|
-$4.64 M
|
-$10.46 M
|
-$19.39 M
|
-$18.65 M
|
-$4.78 M
|
-$5.34 M
|
| Income Before Tax |
$348.33 M |
$248.92 M |
$248.52 M |
$129.30 M |
-$72.25 M |
-$79.79 M |
$61.61 M |
-$101.86 M |
-$32.23 M |
-$68.38 M |
| Income Before Tax Ratio
|
0.42
|
0.38
|
0.56
|
0.48
|
-0.37
|
-0.53
|
0.19
|
-0.69
|
-0.24
|
-0.91
|
| Income Tax Expense |
$66.74 M |
$46.79 M |
-$154.19 M |
$217,000.00 |
-$11,000.00 |
$537,000.00 |
-$1.36 M |
$1.16 M |
$3.52 M |
$3.82 M |
| Net Income |
$281.59 M |
$202.13 M |
$402.71 M |
$129.09 M |
-$72.24 M |
-$80.33 M |
$62.97 M |
-$103.02 M |
-$32.23 M |
-$68.38 M |
| Net Income Ratio |
0.34 |
0.31 |
0.91 |
0.48 |
-0.37 |
-0.53 |
0.2 |
-0.7 |
-0.24 |
-0.91 |
| EPS |
2.13 |
1.48 |
2.86 |
0.95 |
-0.5 |
-0.56 |
0.46 |
-0.81 |
-0.25 |
-0.56 |
| EPS Diluted |
2.1 |
1.44 |
2.74 |
0.91 |
-0.5 |
-0.56 |
0.45 |
-0.81 |
-0.25 |
-0.56 |
| Weighted Average Shares
Out |
$131.93 M
|
$136.84 M
|
$140.65 M
|
$136.21 M
|
$144.33 M
|
$143.45 M
|
$136.42 M
|
$127.19 M
|
$126.70 M
|
$122.69 M
|
| Weighted Average Shares
Out Diluted |
$134.20 M
|
$140.61 M
|
$146.80 M
|
$141.46 M
|
$144.33 M
|
$143.60 M
|
$139.07 M
|
$127.96 M
|
$126.70 M
|
$122.69 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
